NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Lucid Diagnostics Inc. (LUCD) Stock Analysis

Lucid Diagnostics Inc. (LUCD) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

LUCD

$0.94

−$0.01 (−1.16%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LUCD with… →

LUCD Key Statistics

As of Sep 4, 2026
Trading
Open
$0.94
Previous Close
$0.95
Day's Range
0.93–0.96
52-Week Range
0.86–1.63
Volume
1.02M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.10
Valuation
Market Cap
$179.40M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
32.95
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.40
Financials (FY)
Revenue (FY)
$4.71M+8.28%
Net Income (FY)
−$58.01M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
190.95M
1-Year Return
−31.88%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.39M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LUCD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−13.76%
2025+33.09%
2024−41.91%
2023+3.68%
2022−74.67%
2021 (partial year)−54.34%

As of September 4, 2026.

LUCD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.71M−$58.01M−1232.7%
2024$4.35M−$45.53M−1047.6%
2023$2.43M−$52.67M−2169.1%
2022$377.00K−$56.17M−14899.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.71M−$1.96M−$49.64M−$58.01M−1232.7%
2024$4.35M−$2.75M−$46.05M−$45.53M−1047.6%
2023$2.43M−$3.55M−$48.48M−$52.67M−2169.1%
2022$377.00K−$3.24M−$56.25M−$56.17M−14899.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LUCD Valuation vs Medical Devices Median

Median of 151 stocks
MetricLUCDMedical Devices medianvs median
P/S ratio32.952.9811.1x the median
Profit margin0.00%−1.69%1.7 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Lucid Diagnostics Inc. (LUCD) at $179.40M. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 82.

The most recent close on file for LUCD is $0.94, dated September 4, 2026. That is −$0.01 (−1.16%) against the previous close. Over the past 52 weeks the price has ranged from $0.86 to $1.63. The latest close sits 9.18% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.71M. That is +8.28% against the prior fiscal year, when revenue was $4.35M. The same year closed with a net loss of $58.01M. Profit margin runs at 0%. That is 1.7 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are −0.4.

Across the 4 fiscal years on file, revenue moves from $377.00K in 2022 to $4.71M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 32.95 times revenue. On price-to-sales that is 11.1 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 1.1. Daily returns over the trailing 4 years annualize to a volatility of 64.84%. The trailing one-year price return is −31.88%. Measured over 3 years, that is −15.54% a year compounded.

Growth & Income

The record shows no dividend for LUCD.

Across the complete calendar years on file, 2025 returned +33.09% and 2022 returned −74.67%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the price is −13.76%.

Peer Comparison

Lucid Diagnostics Inc. (LUCD) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lucid Diagnostics Inc. LUCD $179.40M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Lucid Diagnostics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Visit website →